What is Bioventus?
Bioventus specializes in developing and commercializing clinically effective, cost-efficient medical treatments that leverage the body's natural healing processes. The company's strategy involves a multi-pronged approach encompassing internal product development, strategic acquisitions, and distribution partnerships. This focus on active healing innovations positions Bioventus to address a growing demand for advanced therapeutic options in the healthcare market.
How much funding has Bioventus raised?
Bioventus has raised a total of $116M across 2 funding rounds:
Debt
$12M
Stock Offering
$104M
Debt (2014): $12M with participation from Alcentra Capital Corporation
Stock Issuance/Offering (2021): $104M, investors not publicly disclosed
Key Investors in Bioventus
Alcentra Capital Corporation
Alcentra Capital Corporation is a provider of debt and equity financing for middle-market companies, aiming to generate risk-adjusted returns through debt investments. It operates as a business development company focused on current income generation.
What's next for Bioventus?
With substantial enterprise-level backing and a recent strategic investment, Bioventus is poised for accelerated expansion and innovation. The company's trajectory suggests a focus on scaling its product portfolio and market reach, potentially through further R&D investments or strategic acquisitions. This financial strength enables Bioventus to continue its mission of bringing cutting-edge active healing solutions to patients worldwide, reinforcing its leadership in the medical device industry.
See full Bioventus company page
